title: Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies.
abstract: Human cytomegalovirus (hCMV) is prevalent worldwide with infection generally being asymptomatic. Nevertheless, hCMV infection can lead to significant morbidity and mortality. Primary infection of seronegative women or reactivation/re-infection of seropositive women during pregnancy can result in transmission to the fetus, leading to severe neurological defects. In addition, hCMV is the most common viral infection in immunosuppressed organ transplant recipients and can produce serious complications. Hence, a safe and effective vaccine to prevent hCMV infection is an unmet medical need. Neutralizing antibodies to several hCMV glycoproteins, and complexes thereof, have been identified in individuals following hCMV infection. Interestingly, a portion of the CMV-specific neutralizing antibody responses are directed to epitopes found on glycoprotein complexes but not the individual proteins. Using an alphavirus replicon particle (VRP) vaccine platform, we showed that bicistronic VRPs encoding hCMV gH and gL glycoproteins produce gH/gL complexes in vitro. Furthermore, mice vaccinated with these gH/gL-expressing VRPs produced broadly cross-reactive complement-independent neutralizing antibodies to hCMV. These neutralizing antibody responses were of higher titer than those elicited in mice vaccinated with monocistronic VRPs encoding gH or gL antigens, and they were substantially more potent than those raised by VRPs encoding gB. These findings underscore the utility of co-delivery of glycoprotein components such as gH and gL for eliciting potent, broadly neutralizing immune responses against hCMV, and indicate that the gH/gL complex represents a potential target for future hCMV vaccine development.
authors.affiliation: Novartis Vaccines and Diagnostics, 350 Massachusetts Ave., Cambridge, MA 02139, United States.
authors.forename: Rebecca J
authors.initials: RJ
authors.lastname: Loomis
authors.forename: Anders E
authors.initials: AE
authors.lastname: Lilja
authors.forename: James
authors.initials: J
authors.lastname: Monroe
authors.forename: Kara A
authors.initials: KA
authors.lastname: Balabanis
authors.forename: Luis A
authors.initials: LA
authors.lastname: Brito
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Palladino
authors.forename: Michael
authors.initials: M
authors.lastname: Franti
authors.forename: Christian W
authors.initials: CW
authors.lastname: Mandl
authors.forename: Susan W
authors.initials: SW
authors.lastname: Barnett
authors.forename: Peter W
authors.initials: PW
authors.lastname: Mason
mesh_terms: D000524:Alphavirus / Q000235:genetics; D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood*; D000914:Antibodies, Viral / Q000097:blood*; D003429:Cross Reactions; D022482:Cytomegalovirus Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D005260:Female; D005822:Genetic Vectors; D051379:Mice; D008807:Mice, Inbred BALB C; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology*; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology*
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D022482:Cytomegalovirus Vaccines; C077406:UL115 protein, Human herpesvirus 5; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014764:Viral Proteins; C499358:glycoprotein H, Human cytomegalovirus